WEKO3
アイテム
PD-L1をターゲットするPET診断及びがん免疫治療用の新規標識ペプチドの開発研究
https://repo.qst.go.jp/records/66904
https://repo.qst.go.jp/records/66904a67d514c-2865-4763-bfa7-77c69fa767dc
| Item type | 会議発表用資料 / Presentation(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2018-09-12 | |||||
| タイトル | ||||||
| タイトル | PD-L1をターゲットするPET診断及びがん免疫治療用の新規標識ペプチドの開発研究 | |||||
| 言語 | ||||||
| 言語 | jpn | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_c94f | |||||
| 資源タイプ | conference object | |||||
| アクセス権 | ||||||
| アクセス権 | metadata only access | |||||
| アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
| 著者 |
Kuan, Hu
× Kuan, Hu× 謝, 琳× 破入, 正行× 張, 明栄× Hu Kuan× 謝 琳× 破入 正行× 張 明栄 |
|||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | Background: Programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) are recognized as promising targets for cancer immunotherapy. Binding of PD-L1 to PD-1 determines a downregulation of T-cell effector functions in cancer patients, inhibiting the antitumor immune response and leading to T-cell exhaustion. Blockade of PD-1/PD-L1 can strengthen the function of effector T cells and increase their production of cytokines through reactivation. Current medication directed toward the PD-1/PD-L1 axis includes monoclonal antibodies. Although great progress has been made, therapeutic antibodies exhibit several disadvantages such as: (1) limited tissue and tumor penetration, (2) lacking oral bioavailability, (3) immunogenicity, and (4) difficult production and high cost. Moreover, current PD-1/PD-L1 axis directed monoclonal antibodies lead to a tumor response only in a small fraction of all known tumor types. Design and Methods: The research of peptide modulator of PD-1/PD-L1 PPIs is significant for both imaging of PD-L1 of the tumor immune microenvironment and anti-cancer therapy. The main goal of this project is to develop radiolabeled PD-L1 peptide modulators with high binding affinity and high specificity. Moreover, as proof-of-concept, this project will demonstrate peptide for radiotherapy and imaging. The bacteria surface display screened a lead peptide TPP-1. Then molecular dynamics docking was performed. Based on the complex structure, the peptide was bound PD-L1 protein with β-hairpin conformation. We then labelled the peptide with 64Cu. The PET imaging of peptide in MDA-231 xenograft mice will be performed. The distribution in vivo will be quantitatively analyzed. After that, peptide cyclization strategies will be utilized to stabilize the peptide into β-hairpin conformation. Results: 1. TPP-1 peptide binds to PD-L1 protein in β-hairpin Conformation. 2. The C- terminal of the peptide is a well-defined β-hairpin structure, however, the N-terminal of the peptide is a random coil structure. 3. The labelled peptide is very stable in saline, and its half-life in serum is about 6 hours. 4. The labelled peptide was majorly metabolized by liver and kidney. It will be excreted by urethra. 5. The labelled peptide has some specific accumulation in spleen in normal mice. Conclusion: TPP-1 peptide is a potential PET tracer for PD-L1 imaging and a lead compound for immune checkpoint therapy. Through peptide stapling technique to constrain the peptide into β-hairpin, this peptide is capable of oral administration for Immunol cancer therapy. |
|||||
| 会議概要（会議名, 開催地, 会期, 主催者等） | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | 第2回日本核医学会分科会 放射性薬品科学研究会 第18回放射性医薬品・画像診断薬研究会 | |||||
| 発表年月日 | ||||||
| 日付 | 2018-09-08 | |||||
| 日付タイプ | Issued | |||||
